Home > Result Summaries: Compounds > Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine > Result Summary for 208127/120

Result Summary for 208127/120

Result Summary

Protocol ID:	208127/120
Clinical Study ID:	208127/120 (HAB-120)
Official Title:	A phase III, open, randomized, multicenter, multicountry study to compare the reactogenicity and evaluate the safety and immunogenicity of GSK Bios’ combined hepatitis A/hepatitis B vac admin according to a 0-6 mth schedule by intramuscular injection versus TWINRIX™ JUNIOR admin in healthy children
Phase:	phase 3
Study Indications or Diseases:	Hepatitis A, Hepatitis B
Generic Name:	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine
Trade/Product Name:	Twinrix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Roberton D et al. (2005) Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1–11-year-old children. Vaccine. 23 (43): 5099-5105. Roberton D et al. Reactogenicity and Immunogenicity profile of a two-dose combined vaccine against hepatitis A and B in children. Abstract presented at the 9th National Immunisation/1st PHAA Asia Pacific Vaccine Preventable Diseases, Cairns, Queensland, Australia, 19-20 August 2004. Roberton D et al. Two-dose combined vaccine against hepatitis A and B in children. Abstract presented at the 43th ICAAC conference, Chicago, US, 14-17 September 2003. Roberton D et al. Reactogenicity and Immunogenicity profile of a two-dose combined vaccine against hepatitis A and B in children. Abstract presented at the Asian Congress of Pediatircs, Bangkok, Thailand. 2-7 Nov 2003.